Speed
43 days to first decision for all manuscripts
63 days to first decision for reviewed manuscripts only
152 days from submission to acceptance
18 days from acceptance to publication
Citation Impact
3.054 - 2-year Impact Factor
3.497 - 5-year Impact Factor
1.315 - Source Normalized Impact per Paper (SNIP)
1.051 - SCImago Journal Rank (SJR)
Usage
917,107 Downloads (2021)
517 Altmetric mentions
Articles
Page 60 of 64
-
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P255
-
A case with SLE and Pseudohypoparathyreoidism
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P253 -
Use of Rituximab in child with SLE and myocardial involvement
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P251 -
Rituximab for treatment of severe lupus nephritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P249 -
A 5 year old boy with Cutaneous Lupus
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P247 -
Neuromyelitis optica associated with systemic autoimmune diseases in children
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P245 -
Treatment of calcinosis with biphosphonates in juvenile dermatomyositis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P220 -
Abstract withdrawn
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P216 -
Differences in therapeutic approach to juvenile dermatomyositis between Europe and Latin America
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P214 -
Different pattern of synthesis and secretion of IL-1beta in patients with CIAS-1 and TNFRSF1A mutations responding to IL-1 blockade
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P212 -
Clinical phenotype and CARD15 gene mutation with Blau Syndrome in Chinese children and their parents
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P210 -
The endogenous TLR-4 ligands MRP8/14 as biomarkers of inflammation in Familial Mediterranean Fever (FMF)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P208 -
Characteristics of a PFAPA cohort in a single European centre
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P184 -
International PFAPA syndrome registry: cohort of 214 patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P182 -
Familial Mediterranean Fever (FMF) before the age of one year
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P180 -
Prospective validation of the diagnostic score for molecular analysis of hereditary autoinflammatory syndromes in Italian children with periodic fever
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P178 -
Familial Mediterranean Fever (FMF) and renal disease: first report on 29 Sicilian patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P176 -
Effect of Botulinum Toxin type-A (Botox®) on neck pain and craniocervical headaches caused by trapezius spasm in a child with generalised joint hypermobility resulting from Noonan's Syndrome
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P174 -
Effectiveness of the treatment with intravenous pamidronate in children with rheumatic diseases
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P145 -
TNF-alfa blockers- promising therapy for chronic uveitis in very young children
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P143 -
Hypokalemic paralysis revealing Sjögren's syndrome (case report)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P141 -
A rare case of sarcoid osteitis in a child with response to methotrexate
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P139 -
Chronic granulomatous disease in an infant with sweet syndrome
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P137 -
Comparison of the accuracy of different definitions of clinical remission (CR) and minimal disease activity (MDA) in juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P112 -
The Dutch translation of the Childhood Health Assessment Questionnaire: an explorative study of the ceiling effect
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P110 -
Does incorporation of aids/devices and help, make a difference in the childhood health assessment questionnaire disability index? Analysis from the printo juvenile idiopathic arthritis database
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P108 -
Preliminary validation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 403 clinic patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P106 -
Performance of different sets of criteria for clinical response evaluation in a non-selected cohort of juvenile idiopathic arthritis (JIA) patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P104 -
Exploring the ceiling effect of the revised Childhood Health Assessment Questionnaire in a European patient sample
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P102 -
Ocular threat in juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P83 -
Enthesitis related arthritis as the early stage of juvenile spondyloarthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P81 -
Efficacy of oral versus subcutaneous methotrexate in children with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P79 -
Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P77 -
Collaboration in long term follow-up of juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P75 -
Juvenile idiopathic arthritis (JIA) and early diagnosis of temporo-mandibular joint (TMJ) disorders
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P73 -
The role of antibodies to mutated citrulinated vimentin (anti-MCV) in juvenile idiopathic arthritis patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P69 -
Efficacy of a second TNF blocker, when the first one failed, in patients with juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P44 -
Juvenile Psoriatic Arthritis (JPsA) clinical features and outcome of 119 patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P42 -
When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P40 -
DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P38 -
Anti-tumour necrosis factor (anti-TNF) in the treatment of juvenile idiopathic arthritis-associated uveitis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P36 -
14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S31 -
13.4 High frequency of CNS involvement in linear scleroderma of the face
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S27 -
12.3 Long-term follow up of patients with CINCA syndrome: efficacy and tolerability of Anakinra treatment
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S25 -
9.4 Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, autoantibody clustering and clinical correlations
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S23 -
8.5 Predictors of long-term outcome of Juvenile Dermatomyositis (JDM): a Multicenter, Multinational Study of 490 patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S19 -
3.4 Physical activity in adolescents with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S6 -
2.4 Magnetic resonance imaging, ultrasonography and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S4 -
2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S2 -
Analysis of the classical, alternative, and MBL pathways of the complement system in juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P1